CN106617109A - 一种肝病改善治疗的功能营养组合物及其制备方法 - Google Patents
一种肝病改善治疗的功能营养组合物及其制备方法 Download PDFInfo
- Publication number
- CN106617109A CN106617109A CN201611034735.1A CN201611034735A CN106617109A CN 106617109 A CN106617109 A CN 106617109A CN 201611034735 A CN201611034735 A CN 201611034735A CN 106617109 A CN106617109 A CN 106617109A
- Authority
- CN
- China
- Prior art keywords
- parts
- calcium
- nutrition composition
- hepatopathy
- improves
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 36
- 230000035764 nutrition Effects 0.000 title claims abstract description 35
- 208000019423 liver disease Diseases 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 57
- 229940088594 vitamin Drugs 0.000 claims abstract description 23
- 239000011782 vitamin Substances 0.000 claims abstract description 23
- 210000004185 liver Anatomy 0.000 claims abstract description 22
- 239000000843 powder Substances 0.000 claims abstract description 19
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 10
- 239000011707 mineral Substances 0.000 claims abstract description 10
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 8
- 240000007594 Oryza sativa Species 0.000 claims abstract description 7
- 235000007164 Oryza sativa Nutrition 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 7
- 235000009566 rice Nutrition 0.000 claims abstract description 7
- 229960003080 taurine Drugs 0.000 claims abstract description 7
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 6
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 6
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 6
- 235000003599 food sweetener Nutrition 0.000 claims abstract description 5
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 5
- 239000003765 sweetening agent Substances 0.000 claims abstract description 5
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 56
- 238000000855 fermentation Methods 0.000 claims description 33
- 230000004151 fermentation Effects 0.000 claims description 33
- 238000011282 treatment Methods 0.000 claims description 24
- 229930003231 vitamin Natural products 0.000 claims description 22
- 235000013343 vitamin Nutrition 0.000 claims description 22
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 22
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 15
- 239000008103 glucose Substances 0.000 claims description 15
- 239000007836 KH2PO4 Substances 0.000 claims description 13
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 13
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 13
- 229910000396 dipotassium phosphate Inorganic materials 0.000 claims description 13
- 229910052564 epsomite Inorganic materials 0.000 claims description 13
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 13
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 13
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims description 13
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 claims description 13
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 13
- 239000000306 component Substances 0.000 claims description 12
- 239000012141 concentrate Substances 0.000 claims description 12
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 10
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 claims description 10
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 10
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 10
- 108010038983 glycyl-histidyl-lysine Proteins 0.000 claims description 10
- 239000002131 composite material Substances 0.000 claims description 9
- 239000012530 fluid Substances 0.000 claims description 9
- 235000010755 mineral Nutrition 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 238000000227 grinding Methods 0.000 claims description 6
- 239000002054 inoculum Substances 0.000 claims description 6
- 239000012533 medium component Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 238000000108 ultra-filtration Methods 0.000 claims description 6
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 6
- 102000009027 Albumins Human genes 0.000 claims description 5
- 108010088751 Albumins Proteins 0.000 claims description 5
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 5
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 5
- 108010073771 Soybean Proteins Proteins 0.000 claims description 5
- 229930003268 Vitamin C Natural products 0.000 claims description 5
- 229930003316 Vitamin D Natural products 0.000 claims description 5
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 5
- 229930003427 Vitamin E Natural products 0.000 claims description 5
- 229960000304 folic acid Drugs 0.000 claims description 5
- 235000019152 folic acid Nutrition 0.000 claims description 5
- 239000011724 folic acid Substances 0.000 claims description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 5
- 229960003512 nicotinic acid Drugs 0.000 claims description 5
- 235000001968 nicotinic acid Nutrition 0.000 claims description 5
- 239000011664 nicotinic acid Substances 0.000 claims description 5
- 229940055726 pantothenic acid Drugs 0.000 claims description 5
- 235000019161 pantothenic acid Nutrition 0.000 claims description 5
- 239000011713 pantothenic acid Substances 0.000 claims description 5
- 235000019710 soybean protein Nutrition 0.000 claims description 5
- 235000019154 vitamin C Nutrition 0.000 claims description 5
- 239000011718 vitamin C Substances 0.000 claims description 5
- 235000019166 vitamin D Nutrition 0.000 claims description 5
- 239000011710 vitamin D Substances 0.000 claims description 5
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 5
- 235000019165 vitamin E Nutrition 0.000 claims description 5
- 229940046009 vitamin E Drugs 0.000 claims description 5
- 239000011709 vitamin E Substances 0.000 claims description 5
- 229940046008 vitamin d Drugs 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 229960005069 calcium Drugs 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 159000000007 calcium salts Chemical class 0.000 claims description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 4
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 4
- 159000000003 magnesium salts Chemical class 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 150000003751 zinc Chemical class 0.000 claims description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000004383 Steviol glycoside Substances 0.000 claims description 3
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 235000021329 brown rice Nutrition 0.000 claims description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 3
- 239000001110 calcium chloride Substances 0.000 claims description 3
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 3
- 235000011148 calcium chloride Nutrition 0.000 claims description 3
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 3
- 239000001354 calcium citrate Substances 0.000 claims description 3
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 3
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 3
- 230000035784 germination Effects 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 3
- 239000001095 magnesium carbonate Substances 0.000 claims description 3
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 3
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 235000019411 steviol glycoside Nutrition 0.000 claims description 3
- 229930182488 steviol glycoside Natural products 0.000 claims description 3
- 150000008144 steviol glycosides Chemical class 0.000 claims description 3
- 235000019202 steviosides Nutrition 0.000 claims description 3
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 3
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 claims description 3
- 239000011746 zinc citrate Substances 0.000 claims description 3
- 235000006076 zinc citrate Nutrition 0.000 claims description 3
- 229940068475 zinc citrate Drugs 0.000 claims description 3
- 239000011670 zinc gluconate Substances 0.000 claims description 3
- 235000011478 zinc gluconate Nutrition 0.000 claims description 3
- 229960000306 zinc gluconate Drugs 0.000 claims description 3
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 3
- 229960001763 zinc sulfate Drugs 0.000 claims description 3
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 3
- YTBSYETUWUMLBZ-UHFFFAOYSA-N D-Erythrose Natural products OCC(O)C(O)C=O YTBSYETUWUMLBZ-UHFFFAOYSA-N 0.000 claims description 2
- YTBSYETUWUMLBZ-IUYQGCFVSA-N D-erythrose Chemical compound OC[C@@H](O)[C@@H](O)C=O YTBSYETUWUMLBZ-IUYQGCFVSA-N 0.000 claims description 2
- 206010056474 Erythrosis Diseases 0.000 claims description 2
- 229920001202 Inulin Polymers 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 claims description 2
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 claims description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 2
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 claims description 2
- 239000000292 calcium oxide Substances 0.000 claims description 2
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- MKJXYGKVIBWPFZ-CEOVSRFSSA-L calcium;(2s)-2-hydroxypropanoate Chemical compound [Ca+2].C[C@H](O)C([O-])=O.C[C@H](O)C([O-])=O MKJXYGKVIBWPFZ-CEOVSRFSSA-L 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 2
- MHJAJDCZWVHCPF-UHFFFAOYSA-L dimagnesium phosphate Chemical compound [Mg+2].OP([O-])([O-])=O MHJAJDCZWVHCPF-UHFFFAOYSA-L 0.000 claims description 2
- 229930182479 fructoside Natural products 0.000 claims description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 2
- 229940029339 inulin Drugs 0.000 claims description 2
- 239000000832 lactitol Substances 0.000 claims description 2
- 235000010448 lactitol Nutrition 0.000 claims description 2
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 2
- 229960003451 lactitol Drugs 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000001755 magnesium gluconate Substances 0.000 claims description 2
- 235000015778 magnesium gluconate Nutrition 0.000 claims description 2
- 229960003035 magnesium gluconate Drugs 0.000 claims description 2
- OVGXLJDWSLQDRT-UHFFFAOYSA-L magnesium lactate Chemical compound [Mg+2].CC(O)C([O-])=O.CC(O)C([O-])=O OVGXLJDWSLQDRT-UHFFFAOYSA-L 0.000 claims description 2
- 239000000626 magnesium lactate Substances 0.000 claims description 2
- 235000015229 magnesium lactate Nutrition 0.000 claims description 2
- 229960004658 magnesium lactate Drugs 0.000 claims description 2
- 239000000395 magnesium oxide Substances 0.000 claims description 2
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 239000004246 zinc acetate Substances 0.000 claims description 2
- 229960000314 zinc acetate Drugs 0.000 claims description 2
- 235000013904 zinc acetate Nutrition 0.000 claims description 2
- 239000011592 zinc chloride Substances 0.000 claims description 2
- 235000005074 zinc chloride Nutrition 0.000 claims description 2
- 229960001939 zinc chloride Drugs 0.000 claims description 2
- 239000011576 zinc lactate Substances 0.000 claims description 2
- 235000000193 zinc lactate Nutrition 0.000 claims description 2
- 229940050168 zinc lactate Drugs 0.000 claims description 2
- 239000011787 zinc oxide Substances 0.000 claims description 2
- 229960001296 zinc oxide Drugs 0.000 claims description 2
- 235000014692 zinc oxide Nutrition 0.000 claims description 2
- 229930003451 Vitamin B1 Natural products 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960003495 thiamine Drugs 0.000 claims 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims 1
- 235000019731 tricalcium phosphate Nutrition 0.000 claims 1
- 229940078499 tricalcium phosphate Drugs 0.000 claims 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims 1
- 235000010374 vitamin B1 Nutrition 0.000 claims 1
- 239000011691 vitamin B1 Substances 0.000 claims 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 abstract description 10
- 229910021529 ammonia Inorganic materials 0.000 abstract description 5
- 210000005229 liver cell Anatomy 0.000 abstract description 5
- 230000004060 metabolic process Effects 0.000 abstract description 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 5
- 239000008280 blood Substances 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 abstract description 4
- 230000003908 liver function Effects 0.000 abstract description 4
- 235000018102 proteins Nutrition 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 abstract description 4
- 102000004169 proteins and genes Human genes 0.000 abstract description 4
- 230000008929 regeneration Effects 0.000 abstract description 4
- 238000011069 regeneration method Methods 0.000 abstract description 4
- 235000013305 food Nutrition 0.000 abstract description 3
- 230000035876 healing Effects 0.000 abstract description 3
- 238000011084 recovery Methods 0.000 abstract description 3
- 235000015097 nutrients Nutrition 0.000 abstract description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 abstract 1
- 108010046377 Whey Proteins Proteins 0.000 abstract 1
- 102000007544 Whey Proteins Human genes 0.000 abstract 1
- 229920001542 oligosaccharide Polymers 0.000 abstract 1
- 150000002482 oligosaccharides Chemical class 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 235000021119 whey protein Nutrition 0.000 abstract 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 23
- 230000006870 function Effects 0.000 description 13
- 229960003180 glutathione Drugs 0.000 description 11
- 239000002609 medium Substances 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 239000000047 product Substances 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 235000019155 vitamin A Nutrition 0.000 description 4
- 239000011719 vitamin A Substances 0.000 description 4
- 229940045997 vitamin a Drugs 0.000 description 4
- 244000197580 Poria cocos Species 0.000 description 3
- 235000008599 Poria cocos Nutrition 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 2
- 235000003097 Artemisia absinthium Nutrition 0.000 description 2
- 240000001851 Artemisia dracunculus Species 0.000 description 2
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 2
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 2
- 241000132012 Atractylodes Species 0.000 description 2
- 244000045232 Canavalia ensiformis Species 0.000 description 2
- 235000010520 Canavalia ensiformis Nutrition 0.000 description 2
- 235000010518 Canavalia gladiata Nutrition 0.000 description 2
- 235000007516 Chrysanthemum Nutrition 0.000 description 2
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 2
- 244000163122 Curcuma domestica Species 0.000 description 2
- 235000003392 Curcuma domestica Nutrition 0.000 description 2
- 235000002722 Dioscorea batatas Nutrition 0.000 description 2
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 2
- 240000001811 Dioscorea oppositifolia Species 0.000 description 2
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- 244000241838 Lycium barbarum Species 0.000 description 2
- 235000015459 Lycium barbarum Nutrition 0.000 description 2
- 241000218231 Moraceae Species 0.000 description 2
- 235000008708 Morus alba Nutrition 0.000 description 2
- 244000170916 Paeonia officinalis Species 0.000 description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940124277 aminobutyric acid Drugs 0.000 description 2
- 239000001138 artemisia absinthium Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 235000003373 curcuma longa Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 235000021196 dietary intervention Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 235000013976 turmeric Nutrition 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000006264 Asimina triloba Nutrition 0.000 description 1
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 241001233914 Chelidonium majus Species 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- 241000522190 Desmodium Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000157511 Oldenlandia Species 0.000 description 1
- 240000001659 Oldenlandia diffusa Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 244000153955 Reynoutria sachalinensis Species 0.000 description 1
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- YSMRWXYRXBRSND-UHFFFAOYSA-N TOTP Chemical compound CC1=CC=CC=C1OP(=O)(OC=1C(=CC=CC=1)C)OC1=CC=CC=C1C YSMRWXYRXBRSND-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- SRBFZHDQGSBBOR-LECHCGJUSA-N alpha-D-xylose Chemical compound O[C@@H]1CO[C@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-LECHCGJUSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 1
- 229940095618 calcium glycerophosphate Drugs 0.000 description 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- -1 matter Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229960003487 xylose Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/315—Zinc compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明属于功能营养食品领域,具体涉及一种肝病改善治疗的功能营养组合物及其制备方法。所述营养组合物包括浓缩乳清蛋白、大豆分离蛋白、白蛋白肽粉、肝肽粉、牛磺酸、γ‑氨基丁酸、磷脂、低聚糖、酵母培养物、麦芽糊精、糙米粉、甜味剂、复合矿物质、复合维生素,通过合理的营养干预,改善各类肝病患者的营养代谢状态、降低对肝细胞的损害、促进肝细胞再生、促进肝功能的恢复,降低肝病患者的血氨水平,促进各类肝病患者的治愈。
Description
技术领域:
本发明属于功能营养食品领域,具体涉及一种肝病改善治疗的功能营养组合物及其制备方法。
背景技术:
肝脏是身体内以代谢功能为主的一个器官,并在身体里面扮演着去氧化,储存肝糖,分泌性蛋白质的合成等角色。肝脏对来自体内和体外的许多非营养性物质如各种药物、毒物以及体内某些代谢产物,具有生物转化作用,通过新陈代谢将它们彻底分解或以原形排出体外,这种作用也被称作“解毒功能”,某些毒物经过生物转化,可以转变为无毒或毒性较小,易于排泄的物质。但是肝脏也容易受到病毒的侵害,患上如A型或B型肝炎、中毒性肝炎、肝癌或是肝硬化等疾病。临床上大多数脂肪肝、肝硬化和重症肝炎病人,在药物治疗的同时必须给予适当的营养治疗,以调节肝脏代谢、减轻肝脏负荷、改善肝脏微环境、促进疾病转归。研究证实,营养治疗在多种疾病治疗及促进疾病转归中起关键作用。
中国发明专利ZL 201310024664.7公开了一种保肝营养组合物,按重量份计包括,木瓜超微粉18-22份,虎杖超微粉8-12份,大枣超微粉8-12份,山楂超微粉7-12份,茯苓粉5-15份和藤茶超微粉3-8份,其配方合理,原料为超微粉,最大程度保留了生物学活性,提高了人体生物利用度,将保肝营养组合物用于制备保肝营养食品,肝病患者食用后能够有效调理肝细胞功能,促进脂肪粒分解代谢,显著改善肝脏微环境,促进坏死组织再生,减轻肝脏代谢负荷,促进疾病恢复。
中国发明专利ZL 200810305820.6公开了一种治疗慢性乙肝的营养保健品,属于营养食品技术领域。由以下配比的原料药物制成的药剂:山药、菊花、桑葚、刀豆、枸杞、生地、太子参、甘草、大枣、柴胡、白芍、白术、茯苓、青皮、茵陈、郁金、白花蛇舌草、半枝莲、徐长卿、金钱草、大青叶。以柴胡、白芍、白术、茯苓、甘草疏肝解郁以条达肝脏,茵陈、白花蛇舌草、徐长卿等药清热解毒、利湿通络,青皮、郁金疏肝理气,山药、菊花、桑葚、刀豆、枸杞、生地、太子参等药补益肝肾、健脾和胃。该发明的中药组合物能阻断和清除乙肝病毒,使病毒标记转阴,同时还能增强机体免疫力、恢复肝功。
但现有技术大多采用天然植物或中草药作为主要成分,存在口味差、营养不够全面以及见效慢等缺点。本发明将提供一种以整蛋白、肽类、脂类、膳食纤维、碳水化合物、矿物质、维生素等组成的营养组合物,通过合理的营养干预,改善各类肝病患者的营养代谢状态、降低对肝细胞的损害、促进肝细胞再生、促进肝功能的恢复,降低肝病患者的血氨水平,促进各类肝病患者的治愈。
发明内容:
为了解决上述技术问题,本发明将提供一种肝病改善治疗的功能营养组合物及其制备方法。
所述营养组合物包括以下重量份数的组分:浓缩乳清蛋白5-50份,大豆分离蛋白5-50份,白蛋白肽粉0.1-5份,肝肽粉0.1-5份,牛磺酸0.1-1份,γ-氨基丁酸0.5-3份,磷脂2-8份,低聚糖0.5-5份,酵母培养物0.01-2份,麦芽糊精5-50份,糙米粉5-50份,甜味剂0.05-8份,复合矿物质0.01-2份,复合维生素0.05-1份;
所述的低聚糖为菊粉、低聚木糖或低聚半乳糖中的任意一种;
优选地,所述甜味剂为木糖醇、甜菊糖苷、乳糖醇、赤鲜糖醇、罗汉果糖苷中的任意一种;
所述复合矿物质重量份数组成如下:钙盐10份、镁盐8份、锌盐1份;
所述钙盐为葡萄糖酸钙、碳酸钙、柠檬酸钙、L-乳酸钙、磷酸氢钙、氯化钙、磷酸三钙(磷酸钙)、甘油磷酸钙、氧化钙、硫酸钙中的任意一种
所述镁盐为乳酸镁、硫酸镁、氯化镁、氧化镁、碳酸镁、磷酸氢镁或葡萄糖酸镁中的任意一种;
所述锌盐为硫酸锌、葡萄糖酸锌、氧化锌、乳酸锌、柠檬酸锌、氯化锌或乙酸锌中的任意一种;
优选地,组分中还可以加入二氧化硅0.01-1.5份;
所述复合维生素重量份数组成如下:维生素A 1份、维生素D 0.002份、维生素E 10份、维生素B1 2份、维生素B2 2份、维生素B6 2份、维生素B12 2份、维生素C 100份、烟酸20份、叶酸1份、泛酸10份;
所述酵母培养物的制备方法如下:
(1)摇瓶培养
取酵母菌株斜面菌种一环,接入装有30mL摇瓶培养基的250mL摇瓶中150rpm,30℃培养30h得种子液;
摇瓶培养基(g/L):(NH4)2SO4 6、葡萄糖35、K2HPO4·3H2O 3、KH2PO4 0.5、酵母粉11、MnSO4 0.1、KCL 0.1、FeSO4 0.1、MgSO4·7H2O 0.1,pH6.0;
(2)5L发酵罐培养
将种子液按10%接种量,接入装有3L发酵培养基的发酵罐中,30℃,通气量6L/min,罐压0.03MPa,500rpm,恒pH6.0条件下进行发酵培养,发酵至30h时,一次性添加终浓度为25-40mmol/L的L-半胱氨酸,再继续发酵18-24h;
发酵培养基(g/L):(NH4)2SO4 10、葡萄糖100、K2HPO4·3H2O 8、KH2PO4 0.5、酵母粉11、MnSO4 0.1、KCL 0.1、FeSO4 0.1、MgSO4·7H2O 0.1,pH6.0;
摇瓶及发酵培养基成分均为食品级;
(3)发酵液经孔径50-1000μm滤膜粗滤,之后将滤液于10-20℃循环超滤浓缩去除水分得固形物含量20-40%浓缩液;浓缩液经真空冷冻干燥、超微粉碎得酵母培养物;
所述酵母菌株具体为酿酒酵母(Saccharomyces cerevisiae)tlj2016,该菌株已于2016年7月15日保藏于中国微生物菌种保藏管理委员会普通微生物中心,保藏编号为CGMCC No.12789,保藏地址:北京市朝阳区北辰西路1号院3号,中国科学院微生物研究所,邮编100101;
所述酿酒酵母tlj2016是一株经过诱变后获得的菌株,tlj2016其葡萄糖耐受能力以及L-半胱氨酸耐受能力均得到提高,一方面在高浓度葡萄糖培养下能够提高细胞密度,另一方面L-半胱氨酸耐受能力的提高将有利于GSH在胞内大量合成,从而提高菌株大规模生产GSH的能力;
由于所述酿酒酵母tlj2016是一株可在外源添加L-半胱氨酸条件下大量合成谷胱甘肽的酵母菌,经发酵后获得酵母培养物,一方面,还原型谷胱甘肽对治疗肝功能异常脂肪肝及对促进肝脏脂肪代谢、降低血脂、修复损伤的肝细胞有明显的功效,另一方面,培养物中含有大量的酵母菌体,能够提供丰富的蛋白质、维生素和酶等生理活性物质;
所述的糙米粉也可以用发芽糙米粉替代;
其余原料均为市售产品。
所述营养组合物的制备方法为:按本领域常规方法将上述组分加工为片剂、粉剂、颗粒剂、口服液等直接服用,每日用量为30~120g。
有益效果:
1、本发明所提供的产品营养全面,包括母乳化氨基酸谱组成的高蛋白、肽类、适宜脂肪、适宜碳水化合物、矿物元素、维生素、牛磺酸、γ-氨基丁酸,通过合理的营养干预,改善各类肝病患者的营养代谢状态、降低对肝细胞的损害、促进肝细胞再生、促进肝功能的恢复,降低肝病患者的血氨水平,促进各类肝病患者的治愈;
2、本发明所提供的产品还含有酵母培养物,该培养物是由一株经过紫外诱变获得的菌株,在外源添加半胱氨酸的条件下,大量合成谷胱甘肽,还能有效提高产品中的蛋白质、维生素和酶等生理活性物质。
具体实施方式:
实施例1:一种肝病改善治疗的功能营养组合物
一种肝病改善治疗的功能营养组合物,所述营养组合物包括以下重量份数的组分:浓缩乳清蛋白5份,大豆分离蛋白50份,白蛋白肽粉0.1份,肝肽粉5份,牛磺酸0.1份,γ-氨基丁酸3份,磷脂2份,低聚木糖5份,酵母培养物0.01份,麦芽糊精50份,糙米粉5份,木糖醇8份,复合矿物质0.01份,复合维生素1份,二氧化硅1.5份;
按照上述配方比例称取各组分,粉碎,过80目筛,然后混合10min,得粉剂;
所述复合矿物质重量份数组成如下:碳酸钙10份、碳酸镁8份、柠檬酸锌1份;
所述复合维生素重量份数组成如下:维生素A 1份、维生素D 0.002份、维生素E 10份、维生素B1 2份、维生素B2 2份、维生素B6 2份、维生素B12 2份、维生素C 100份、烟酸20份、叶酸1份、泛酸10份;
所述酵母培养物的制备方法如下:
(1)摇瓶培养
取酵母斜面菌种一环,接入装有30mL摇瓶培养基的250mL摇瓶中150rpm,30℃培养30h得种子液;
摇瓶培养基(g/L):(NH4)2SO4 6、葡萄糖35、K2HPO4·3H2O 3、KH2PO4 0.5、酵母粉11、MnSO4 0.1、KCL 0.1、FeSO4 0.1、MgSO4·7H2O 0.1,pH6.0;
(2)5L发酵罐培养
将种子液按10%接种量,接入装有3L发酵培养基的发酵罐中,30℃,通气量6L/min,罐压0.03MPa,500rpm,恒pH6.0条件下进行发酵培养,发酵至30h时,一次性添加终浓度为25mmol/L的L-半胱氨酸,再继续发酵18h;
发酵结束后,测定发酵液中GSH的含量为2346mg/L;
发酵培养基(g/L):(NH4)2SO4 10、葡萄糖100、K2HPO4·3H2O 8、KH2PO4 0.5、酵母粉11、MnSO4 0.1、KCL 0.1、FeSO4 0.1、MgSO4·7H2O 0.1,pH6.0;
摇瓶及发酵培养基成分均为食品级;
(3)发酵液经孔径50μm粗滤,之后将滤液于20℃循环超滤浓缩去除水分得固形物含量20%浓缩液;浓缩液经真空冷冻干燥、超微粉碎得酵母培养物;
所述酵母菌株具体为酿酒酵母(Saccharomyces cerevisiae)tlj2016,保藏编号为CGMCC No.12789;
其余原料均为市售。
实施例2:一种肝病改善治疗的功能营养组合物
一种肝病改善治疗的功能营养组合物,所述营养组合物包括以下重量份数的组分组成:浓缩乳清蛋白50份,大豆分离蛋白5份,白蛋白肽粉5份,肝肽粉0.1份,牛磺酸1份,γ-氨基丁酸0.5份,磷脂8份,低聚半乳糖0.5份,酵母培养物2份,麦芽糊精5份,发芽糙米粉50份,甜菊糖苷0.05份,复合矿物质2份,复合维生素0.05份,二氧化硅1份;
按照上述配方比例称取各组分,粉碎,过80目筛,然后混合10min,得粉剂;
所述复合矿物质重量份数组成如下:柠檬酸钙10份、硫酸镁8份、硫酸锌1份;
所述复合维生素重量份数组成如下:维生素A 1份、维生素D 0.002份、维生素E 10份、维生素B1 2份、维生素B2 2份、维生素B6 2份、维生素B12 2份、维生素C 100份、烟酸20份、叶酸1份、泛酸10份;
所述酵母培养物的制备方法如下:
(1)摇瓶培养
取酵母斜面菌种一环,接入装有30mL摇瓶培养基的250mL摇瓶中150rpm,30℃培养30h得种子液;
摇瓶培养基(g/L):(NH4)2SO4 6、葡萄糖35、K2HPO4·3H2O 3、KH2PO4 0.5、酵母粉11、MnSO4 0.1、KCL 0.1、FeSO4 0.1、MgSO4·7H2O 0.1,pH6.0;
(2)5L发酵罐培养
将种子液按10%接种量,接入装有3L发酵培养基的发酵罐中,30℃,通气量6L/min,罐压0.03MPa,500rpm,恒pH6.0条件下进行发酵培养,发酵至30h时,一次性添加终浓度为25mmol/L的L-半胱氨酸,再继续发酵22h;
发酵结束后,测定发酵液中GSH的含量为2816mg/L;
发酵培养基(g/L):(NH4)2SO4 10、葡萄糖100、K2HPO4·3H2O 8、KH2PO4 0.5、酵母粉11、MnSO4 0.1、KCL 0.1、FeSO4 0.1、MgSO4·7H2O 0.1,pH6.0;
摇瓶及发酵培养基成分均为食品级;
(3)发酵液经孔径1000μm粗滤,之后将滤液于10℃循环超滤浓缩去除水分得固形物含量40%浓缩液;浓缩液经真空冷冻干燥、超微粉碎得酵母培养物;
所述酵母菌株具体为酿酒酵母(Saccharomyces cerevisiae)tlj2016,保藏编号为CGMCC No.12789;
其余原料均为市售。
实施例3:一种肝病改善治疗的功能营养组合物
一种肝病改善治疗的功能营养组合物,所述营养组合物包括以下重量份数的组分组成:浓缩乳清蛋白25份,大豆分离蛋白30份,白蛋白肽粉3份,肝肽粉2份,牛磺酸0.5份,γ-氨基丁酸2份,磷脂5份,低聚木糖2份,酵母培养物1份,麦芽糊精25份,糙米粉30份,赤藓糖醇0.5份,复合矿物质0.1份,复合维生素0.08份;
按照上述配方比例称取各组分,粉碎,过80目筛,然后混合10min,得粉剂;
所述复合矿物质重量份数组成如下:氯化钙10份、氯化镁8份、葡萄糖酸锌1份;
所述复合维生素重量份数组成如下:维生素A 1份、维生素D 0.002份、维生素E 10份、维生素B1 2份、维生素B2 2份、维生素B6 2份、维生素B12 2份、维生素C 100份、烟酸20份、叶酸1份、泛酸10份;
所述酵母培养物的制备方法如下:
(1)摇瓶培养
取酵母斜面菌种一环,接入装有30mL摇瓶培养基的250mL摇瓶中150rpm,30℃培养30h得种子液;
摇瓶培养基(g/L):(NH4)2SO4 6、葡萄糖35、K2HPO4·3H2O 3、KH2PO4 0.5、酵母粉11、MnSO4 0.1、KCL 0.1、FeSO4 0.1、MgSO4·7H2O 0.1,pH6.0;
(2)5L发酵罐培养
将种子液按10%接种量,接入装有3L发酵培养基的发酵罐中,30℃,通气量6L/min,罐压0.03MPa,500rpm,恒pH6.0条件下进行发酵培养,发酵至30h时,一次性添加终浓度为25mmol/L的L-半胱氨酸,再继续发酵24h;
发酵结束后,测定发酵液中GSH的含量为3308mg/L;
发酵培养基(g/L):(NH4)2SO4 10、葡萄糖100、K2HPO4·3H2O 8、KH2PO4 0.5、酵母粉11、MnSO4 0.1、KCL 0.1、FeSO4 0.1、MgSO4·7H2O 0.1,pH6.0;
摇瓶及发酵培养基成分均为食品级;
(3)发酵液经孔径500μm粗滤,之后将滤液于15℃循环超滤浓缩去除水分得固形物含量30%浓缩液;浓缩液经真空冷冻干燥、超微粉碎得酵母培养物;
所述酵母菌株具体为酿酒酵母(Saccharomyces cerevisiae)tlj2016,保藏编号为CGMCC No.12789;
其余成分均为市售。
实施例4 效果实验
(1)将100例年龄18-65岁肝硬化患者随机分A、B组
A组Child-Pugh评分为B级36例,C级14例;B组Child-Pugh评分为B级37例,C级13例;
排除标准:①合并甲肝、丙肝、戊肝、艾滋、梅毒感染及免疫性疾病者;②无法经肠营养者;③合并严重感染、消化道出血、未控制的高血压及糖尿病、肾功能不全、甲状腺功能亢进或减退等疾病者;
A组50例:无营养组合物,食用与B组等热量的碳水化合物;
B组50例:每日服用本发明实施例3制备的产品80g;
同时肝硬化患者均接受常规治疗,包括原发病治疗、保肝药物使用等;
实验周期2个月。
(2)评价指标:
Child-Pugh评分:见表1;
实验结果表明,服用本发明提供的产品有助于帮助肝病患者改善身体状况及各项指标,未发现明显不良反应。
表1 Child-Pugh评分
实施例5 L-半胱氨酸耐受力实验
将出发菌株以及tlj2016斜面菌种各一环,分别接入装有30mL摇瓶培养基的250mL摇瓶中150rpm,30℃培养进行培养,在培养至12h时,向摇瓶中加入不同终浓度的L-半胱氨酸,再培养10h,测定细胞干重,结果如表2、3;
摇瓶培养基(g/L):(NH4)2SO4 6、葡萄糖20、K2HPO4·3H2O 3、KH2PO4 0.5、酵母粉11、MnSO4 0.1、KCL 0.1、FeSO4 0.1、MgSO4·7H2O 0.1,pH6.0;
表2:出发菌株L-半胱氨酸耐受力
L-半胱氨酸浓度mmol/L | 0 | 5 | 10 | 15 | 20 | 40 |
出发菌株干重g/L | 22.6 | 15.7 | 10.2 | 4.3 | 2.2 | 0.8 |
GSH浓度(mg/L) | 35.6 | 46.7 | 43.2 | 40.7 | 37.9 | 25.3 |
表3:tlj2016L-半胱氨酸耐受力
L-半胱氨酸浓度mmol/L | 0 | 5 | 10 | 15 | 20 | 40 |
tlj2016干重g/L | 25.7 | 28.5 | 23.6 | 21.2 | 20.6 | 18.7 |
GSH浓度(mg/L) | 73.2 | 98.3 | 113.5 | 121.7 | 127.5 | 135.8 |
从表2、3的结果可以看出,对于出发菌株,培养基中添加L-半胱氨酸,细胞停止生长,并且开始自溶,导致GSH增长率随着L-半胱氨酸浓度的升高而降低;而低浓度L-半胱氨酸下,tlj2016仍能够缓慢生长,随着L-半胱氨酸浓度的提高,tlj2016菌株的细胞干重缓慢下降,而GSH浓度持续增长,这一结果将有利于GSH生产过程中通过添加前体氨基酸:L-半胱氨酸提促进GSH的生产。
Claims (10)
1.一种肝病改善治疗的功能营养组合物,其特征在于,所述营养组合物包括以下重量份数的组分:浓缩乳清蛋白5-50份,大豆分离蛋白5-50份,白蛋白肽粉0.1-5份,肝肽粉0.1-5份,牛磺酸0.1-1份,γ-氨基丁酸0.5-3份,磷脂2-8份,低聚糖0.5-5份,酵母培养物0.01-2份,麦芽糊精5-50份,糙米粉5-50份,甜味剂0.05-8份,复合矿物质0.01-2份,复合维生素0.05-1份;
所述酵母培养物的制备方法如下:
(1)摇瓶培养
取酵母菌株斜面菌种一环,接入装有30mL摇瓶培养基的250mL摇瓶中150rpm,30℃培养30h得种子液;
(2)发酵罐培养
将种子液按10%接种量,接入装有发酵培养基的发酵罐中,30℃,通气量6L/min,罐压0.03MPa,500rpm,恒pH6.0条件下进行发酵培养,发酵至30h时,一次性添加终浓度为25-40mmol/L的L-半胱氨酸,再继续发酵18-24h;
(3)发酵液经孔径50-1000μm滤膜粗滤,之后将滤液于10-20℃循环超滤浓缩去除水分得固形物含量20-40%浓缩液;浓缩液经真空冷冻干燥、超微粉碎得酵母培养物;
所述酵母菌株具体为酿酒酵母(Saccharomyces cerevisiae)tlj2016,保藏编号为CGMCC No.12789。
2.如权利要求1所述的一种肝病改善治疗的功能营养组合物,其特征在于,
所述摇瓶培养基以g/L计:(NH4)2SO4 6、葡萄糖35、K2HPO4·3H2O 3、KH2PO4 0.5、酵母粉11、MnSO4 0.1、KCL 0.1、FeSO4 0.1、MgSO4·7H2O 0.1,pH6.0;
发酵培养基以g/L计:(NH4)2SO4 10、葡萄糖100、K2HPO4·3H2O 8、KH2PO4 0.5、酵母粉11、MnSO4 0.1、KCL 0.1、FeSO4 0.1、MgSO4·7H2O 0.1,pH6.0;
摇瓶及发酵培养基成分均为食品级。
3.如权利要求1所述的一种肝病改善治疗的功能营养组合物,其特征在于,所述低聚糖为菊粉、低聚木糖或低聚半乳糖中的任意一种。
4.如权利要求1所述的一种肝病改善治疗的功能营养组合物,其特征在于,所述甜味剂为木糖醇、甜菊糖苷、乳糖醇、赤鲜糖醇、罗汉果糖苷中的任意一种。
5.如权利要求1所述的一种肝病改善治疗的功能营养组合物,其特征在于,所述复合矿物质重量份数组成如下:钙盐10份、镁盐8份、锌盐1份;
所述钙盐为葡萄糖酸钙、碳酸钙、柠檬酸钙、L-乳酸钙、磷酸氢钙、氯化钙、磷酸三钙、甘油磷酸钙、氧化钙、硫酸钙中的任意一种;
所述镁盐为乳酸镁、硫酸镁、氯化镁、氧化镁、碳酸镁、磷酸氢镁或葡萄糖酸镁中的任意一种;
所述锌盐为硫酸锌、葡萄糖酸锌、氧化锌、乳酸锌、柠檬酸锌、氯化锌或乙酸锌中的任意一种。
6.如权利要求1所述的一种肝病改善治疗的功能营养组合物,其特征在于,所述复合维生素重量份数组成如下:维生素A1份、维生素D 0.002份、维生素E 10份、维生素B1 2份、维生素B2 2份、维生素B6 2份、维生素B12 2份、维生素C 100份、烟酸20份、叶酸1份、泛酸10份。
7.如权利要求1所述的一种肝病改善治疗的功能营养组合物,其特征在于,所述糙米粉以发芽糙米粉替代。
8.如权利要求1所述的一种肝病改善治疗的功能营养组合物,其特征在于,所述营养组合物还包括二氧化硅0.01-1.5份。
9.如权利要求1-8任意一项所述的肝病改善治疗的功能营养组合物,其特征在于,服用方法为每日用量为30~120g。
10.权利要求1-8任意一项所述的肝病改善治疗的功能营养组合物的制备方法,其特征在于,步骤如下:
(1)酵母培养物的制备方法如下:
①摇瓶培养
取酵母菌株tlj2016斜面菌种一环,接入装有30mL摇瓶培养基的250mL摇瓶中150rpm,30℃培养30h得种子液;
摇瓶培养基以g/L计:(NH4)2SO4 6、葡萄糖35、K2HPO4·3H2O 3、KH2PO4 0.5、酵母粉11、MnSO4 0.1、KCL 0.1、FeSO4 0.1、MgSO4·7H2O 0.1,pH6.0;
②5L发酵罐培养
将种子液按10%接种量,接入装有3L发酵培养基的发酵罐中,30℃,通气量6L/min,罐压0.03MPa,500rpm,恒pH6.0条件下进行发酵培养,发酵至30h时,一次性添加终浓度为25-40mmol/L的L-半胱氨酸,再继续发酵18-24h;
发酵培养基以g/L计:(NH4)2SO4 10、葡萄糖100、K2HPO4·3H2O 8、KH2PO4 0.5、酵母粉11、MnSO4 0.1、KCL 0.1、FeSO4 0.1、MgSO4·7H2O 0.1,pH6.0;
摇瓶及发酵培养基成分均为食品级;
③发酵液经孔径50-1000μm滤膜粗滤,之后将滤液于10-20℃循环超滤浓缩去除水分得固形物含量20-40%浓缩液;浓缩液经真空冷冻干燥、超微粉碎得酵母培养物;
(2)按重量份数称取各组分;
(3)将上述组分加工为片剂、粉剂、颗粒剂、口服液。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611034735.1A CN106617109A (zh) | 2016-11-09 | 2016-11-09 | 一种肝病改善治疗的功能营养组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611034735.1A CN106617109A (zh) | 2016-11-09 | 2016-11-09 | 一种肝病改善治疗的功能营养组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106617109A true CN106617109A (zh) | 2017-05-10 |
Family
ID=58808972
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611034735.1A Pending CN106617109A (zh) | 2016-11-09 | 2016-11-09 | 一种肝病改善治疗的功能营养组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106617109A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107259234A (zh) * | 2017-06-06 | 2017-10-20 | 北京知药医疗科技有限公司 | 一种无糖的胶原蛋白饮料 |
CN110179107A (zh) * | 2019-07-01 | 2019-08-30 | 北京东方倍力营养科技有限公司 | 一种改善肝脏功能及肝纤维化的全营养组合物 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1450168A (zh) * | 2003-05-09 | 2003-10-22 | 江南大学 | 一种提高产朊假丝酵母发酵生产谷胱甘肽产量的方法 |
CN101220338A (zh) * | 2007-12-24 | 2008-07-16 | 南京华锦生物制品有限公司 | 一种谷胱甘肽生产菌株及其构建方法 |
CN104082656A (zh) * | 2014-06-12 | 2014-10-08 | 广东省农业科学院蚕业与农产品加工研究所 | 一种适合肝病病人的营养膳及其制作方法 |
CN104146142A (zh) * | 2014-07-28 | 2014-11-19 | 四川安益生物科技有限公司 | 一种复合保健食品及其制备方法 |
CN105505801A (zh) * | 2015-12-25 | 2016-04-20 | 湖北泱盛生物科技有限公司 | 一种高产谷胱甘肽的酿酒酵母及其用途 |
CN105768106A (zh) * | 2016-03-23 | 2016-07-20 | 北京东方兴企食品工业技术有限公司 | 一种有助于肝营养改善的功能性食品 |
-
2016
- 2016-11-09 CN CN201611034735.1A patent/CN106617109A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1450168A (zh) * | 2003-05-09 | 2003-10-22 | 江南大学 | 一种提高产朊假丝酵母发酵生产谷胱甘肽产量的方法 |
CN101220338A (zh) * | 2007-12-24 | 2008-07-16 | 南京华锦生物制品有限公司 | 一种谷胱甘肽生产菌株及其构建方法 |
CN104082656A (zh) * | 2014-06-12 | 2014-10-08 | 广东省农业科学院蚕业与农产品加工研究所 | 一种适合肝病病人的营养膳及其制作方法 |
CN104146142A (zh) * | 2014-07-28 | 2014-11-19 | 四川安益生物科技有限公司 | 一种复合保健食品及其制备方法 |
CN105505801A (zh) * | 2015-12-25 | 2016-04-20 | 湖北泱盛生物科技有限公司 | 一种高产谷胱甘肽的酿酒酵母及其用途 |
CN105768106A (zh) * | 2016-03-23 | 2016-07-20 | 北京东方兴企食品工业技术有限公司 | 一种有助于肝营养改善的功能性食品 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107259234A (zh) * | 2017-06-06 | 2017-10-20 | 北京知药医疗科技有限公司 | 一种无糖的胶原蛋白饮料 |
CN110179107A (zh) * | 2019-07-01 | 2019-08-30 | 北京东方倍力营养科技有限公司 | 一种改善肝脏功能及肝纤维化的全营养组合物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104432084B (zh) | 一种调理粉及其制备方法和用途 | |
CN104431741B (zh) | 一种谷物调理粥及其制备方法和用途 | |
CN108272073A (zh) | 一种减肥代餐粉及其制备方法 | |
CN104873761B (zh) | 一种蛹虫草复方制品及其制备方法 | |
CN102090692A (zh) | 一种牡蛎多肽抗疲劳饮料及其制备方法 | |
CN106174474A (zh) | 一种适用于心脑血管疾病患者食用的特膳食品 | |
CN108618126A (zh) | 一种中药复方减肥特殊膳食食品及其制备方法 | |
CN104839707A (zh) | 阴虚体质非全营养配方食品 | |
CN106235325A (zh) | 包含花生幼苗提取物的解酒饮料组合物以及其制造方法 | |
CN104855975A (zh) | 肌肉衰减综合征非全营养配方食品 | |
CN101664180B (zh) | 一种具有保健功效的营养复合剂及其制备方法 | |
CN106617109A (zh) | 一种肝病改善治疗的功能营养组合物及其制备方法 | |
CN110075266A (zh) | 一种养肾固肾补气血的配方及制备方法 | |
CN102657304A (zh) | 一种具有促进消化和缓解体力疲劳双功能的保健食品 | |
CN104739964B (zh) | 一种蜗牛解酒制剂及其制作方法 | |
CN115005437B (zh) | 一种具有解酒护肝功效的酵素饮料及其制备方法 | |
CN114365844B (zh) | 一种调节肠道菌群、提高肠道免疫的竹荪复方保健食品及其制备方法 | |
CN107325163A (zh) | 黄芪种子蛋白及其在抗运动疲劳功能食品中的应用 | |
CN101595985A (zh) | 一种虫草百菇精口服液 | |
CN101530210B (zh) | 一种养生酒 | |
CN102048212B (zh) | 一种保肝护肝饮料及其制备方法 | |
CN110547397A (zh) | 一种肿瘤康复营养代餐食品及其制备方法 | |
CN104432022B (zh) | 一种消除亚健康的混合营养粉及其制作方法 | |
CN113100442B (zh) | 一种蜂王浆龟鳖肽嚼含片及其制备工艺 | |
CN104013853B (zh) | 一种健肾补肾的组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170510 |